Form 8-K - Current report:
SEC Accession No. 0001641172-25-013396
Filing Date
2025-06-03
Accepted
2025-06-03 13:46:13
Documents
14
Period of Report
2025-05-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 46991
2 EX-10.1 ex10-1.htm EX-10.1 22294
  Complete submission text file 0001641172-25-013396.txt   286064

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE tvgn-20250530.xsd EX-101.SCH 3814
4 XBRL DEFINITION FILE tvgn-20250530_def.xml EX-101.DEF 26690
5 XBRL LABEL FILE tvgn-20250530_lab.xml EX-101.LAB 36843
6 XBRL PRESENTATION FILE tvgn-20250530_pre.xml EX-101.PRE 25314
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6061
Mailing Address 15 INDEPENDENCE BOULEVARD, SUITE #210 WARREN NJ 07059
Business Address 15 INDEPENDENCE BOULEVARD, SUITE #210 WARREN NJ 07059 646-807-8832
Tevogen Bio Holdings Inc. (Filer) CIK: 0001860871 (see all company filings)

EIN.: 981597194 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41002 | Film No.: 251018413
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)